Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Gene Amplification”

66 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 66 results

Early research (Phase 1)Study completedNCT01613950
What this trial is testing

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Who this might be right for
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)UnknownNCT05016544
What this trial is testing

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 48
Not applicableStudy completedNCT05902494
What this trial is testing

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 389
Testing effectiveness (Phase 2)Active Not RecruitingNCT06136897
What this trial is testing

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 35
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Testing effectiveness (Phase 2)UnknownNCT05274191
What this trial is testing

An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid Tumors

Who this might be right for
Solid Tumor
Zhongshan Hospital Xiamen University 60
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT06726148
What this trial is testing

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small Cell Lung Cancer
Novartis Pharmaceuticals 280
Early research (Phase 1)Temporarily pausedNCT04650451
What this trial is testing

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Who this might be right for
HER-2 Gene AmplificationHER2-positive Gastric CancerHER2-positive Breast Cancer+2 more
Bellicum Pharmaceuticals 220
Large-scale testing (Phase 3)Study completedNCT00320385
What this trial is testing

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 296
Testing effectiveness (Phase 2)WithdrawnNCT05512182
What this trial is testing

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Who this might be right for
Recurrent/Advanced Gastric Cancer
Yonsei University
Testing effectiveness (Phase 2)UnknownNCT00842998
What this trial is testing

Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Azienda Ospedaliera Ordine Mauriziano di Torino 120
Early research (Phase 1)Ended earlyNCT05511844
What this trial is testing

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER-2 Protein OverexpressionHER-2 Gene Amplification+1 more
Orum Therapeutics USA, Inc. 25
Not applicableUnknownNCT03979911
What this trial is testing

Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer

Who this might be right for
Breast NeoplasmsHER-2 Gene Amplification
University Hospital, Brest 63
Early research (Phase 1)Active Not RecruitingNCT06328738
What this trial is testing

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2 Positive Solid Tumors+2 more
Enliven Therapeutics 275
Testing effectiveness (Phase 2)Study completedNCT02314481
What this trial is testing

Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Who this might be right for
Non-small Cell Lung Cancer
University College, London 50
Testing effectiveness (Phase 2)Study completedNCT00006089
What this trial is testing

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Who this might be right for
Endometrial AdenocarcinomaERBB2 Gene AmplificationRecurrent Uterine Corpus Carcinoma+2 more
National Cancer Institute (NCI) 34
Early research (Phase 1)Active Not RecruitingNCT05650879
What this trial is testing

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Who this might be right for
HER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene Mutation+1 more
Enliven Therapeutics 198
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Testing effectiveness (Phase 2)Ended earlyNCT01774851
What this trial is testing

MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Who this might be right for
HER-2 Gene AmplificationEsophagus CancerGastroesophageal Junction Cancer+1 more
Merrimack Pharmaceuticals 84
Next Page